ABEO Abeona Therapeutics Inc.

+0.03  (+1%)
Previous Close 2.17
Open 2.18
Price To Book 1.01
Market Cap 108,494,652
Shares 49,315,751
Volume 451,411
Short Ratio
Av. Daily Volume 756,348

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data due 2H 2019.
Sanfilippo syndrome type B (MPS IIIB)
Phase 3 trial to be initiated 4Q 2019.
Recessive dystrophic epidermolysis bullosa (RDEB)
Phase 1/2 meeting with FDA 2H 2019 to discuss next steps.
Sanfilippo syndrome type A (MPS IIIA)
Phase 1/2 trial planned. Timing to be announced later in 2019.
CLN1 disease (Infantile Batten disease)

Latest News

  1. Edited Transcript of ABEO earnings conference call or presentation 12-Aug-19 2:00pm GMT
  2. Abeona Therapeutics Inc (ABEO) Q2 2019 Earnings Call Transcript
  3. Abeona Therapeutics (ABEO) Reports Q2 Loss, Misses Revenue Estimates
  4. Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
  5. Analysts Estimate Abeona Therapeutics (ABEO) to Report a Decline in Earnings: What to Look Out for
  6. The LD Micro Index Turns Four Years Old
  7. Penny Stocks to Buy Using Technical Analysis for August 2019
  8. Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA
  9. How Many Abeona Therapeutics Inc. (NASDAQ:ABEO) Shares Did Insiders Buy, In The Last Year?
  10. Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
  11. Here’s What Hedge Funds Think About Abeona Therapeutics Inc (ABEO)
  12. Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
  13. Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
  14. Edited Transcript of ABEO earnings conference call or presentation 14-May-19 2:00pm GMT
  15. Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
  16. Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
  17. Abeona Therapeutics: 1Q Earnings Snapshot
  18. Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
  19. Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting